U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C18H21NO3.2C4H6O6.5H2O
Molecular Weight 988.9786
Optical Activity UNSPECIFIED
Defined Stereocenters 12 / 12
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROCODONE BITARTRATE

SMILES

O.O.O.O.O.O[C@H]([C@@H](O)C(O)=O)C(O)=O.O[C@H]([C@@H](O)C(O)=O)C(O)=O.[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]15CCN(C)[C@H](C4)[C@]5([H])CCC2=O.[H][C@@]67OC8=C(OC)C=CC9=C8[C@@]6%10CCN(C)[C@H](C9)[C@]%10([H])CCC7=O

InChI

InChIKey=JMBRWJAVUIITGV-LNNMZZBZSA-N
InChI=1S/2C18H21NO3.2C4H6O6.5H2O/c2*1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;2*5-1(3(7)8)2(6)4(9)10;;;;;/h2*3,6,11-12,17H,4-5,7-9H2,1-2H3;2*1-2,5-6H,(H,7,8)(H,9,10);5*1H2/t2*11-,12+,17-,18-;2*1-,2-;;;;;/m0011...../s1

HIDE SMILES / InChI

Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H21NO3
Molecular Weight 299.3642
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Benzhydrocodone is a prodrug of hydrocodone. Benzhydrocodone is formed by covalently bonding hydrocodone to benzoic acid. Benzhydrocodone itself is not pharmacologically active, but must be metabolized to hydrocodone by enzymes in the intestinal tract to optimally deliver its pharmacologic effects. Hydrocodone is a full agonist of the opioid receptors with a higher affinity for the mu-opioid receptor. Upon binding, hydrocodone produces an analgesic effect with no ceiling. APADAZ a combination of benzhydrocodone and acetaminophen is FDA approved and indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. APADAZ, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZOHYDRO ER

Approved Use

ZOHYDRO ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Launch Date

2013
Primary
APADAZ

Approved Use

APADAZ is a combination of benzhydrocodone, a prodrug of the opioid agonist hydrocodone, and acetaminophen, and is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Launch Date

2019
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10.1 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
23.6 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
155 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.2 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
55%
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROCODONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
30 mg multiple, oral (total)
Overdose
Dose: 30 mg
Route: oral
Route: multiple
Dose: 30 mg
Co-administed with::
clarithromycin
valproic acid(250 mg, 2 times per day)
Sources:
unhealthy, 5 years
n = 1
Health Status: unhealthy
Condition: cold
Age Group: 5 years
Sex: F
Population Size: 1
Sources:
Other AEs: Adverse event...
Other AEs:
Adverse event (grade 5)
Sources:
160 mg 1 times / day multiple, oral
Highest studied dose
unhealthy, adult
Other AEs: Electrocardiogram QTc interval prolonged...
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
Other AEs: Withdrawal syndrome neonatal...
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
Other AEs: Respiratory depression, Addiction...
Other AEs:
Respiratory depression (grade 5)
Addiction
Sources:
20 mg 1 times / day multiple, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p. 115
unhealthy, adult
n = 296
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 296
Sources: Page: p. 115
Disc. AE: Vomiting, Nausea...
AEs leading to
discontinuation/dose reduction:
Vomiting (1%)
Nausea (1%)
Headache (1%)
Dizziness (1%)
Sources: Page: p. 115
AEs

AEs

AESignificanceDosePopulation
Adverse event grade 5
30 mg multiple, oral (total)
Overdose
Dose: 30 mg
Route: oral
Route: multiple
Dose: 30 mg
Co-administed with::
clarithromycin
valproic acid(250 mg, 2 times per day)
Sources:
unhealthy, 5 years
n = 1
Health Status: unhealthy
Condition: cold
Age Group: 5 years
Sex: F
Population Size: 1
Sources:
Electrocardiogram QTc interval prolonged
160 mg 1 times / day multiple, oral
Highest studied dose
unhealthy, adult
Withdrawal syndrome neonatal
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
pregnant, adult
Health Status: pregnant
Age Group: adult
Sex: F
Sources:
Addiction
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
Respiratory depression grade 5
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
Dizziness 1%
Disc. AE
20 mg 1 times / day multiple, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p. 115
unhealthy, adult
n = 296
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 296
Sources: Page: p. 115
Headache 1%
Disc. AE
20 mg 1 times / day multiple, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p. 115
unhealthy, adult
n = 296
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 296
Sources: Page: p. 115
Nausea 1%
Disc. AE
20 mg 1 times / day multiple, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p. 115
unhealthy, adult
n = 296
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 296
Sources: Page: p. 115
Vomiting 1%
Disc. AE
20 mg 1 times / day multiple, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p. 115
unhealthy, adult
n = 296
Health Status: unhealthy
Age Group: adult
Sex: M+F
Population Size: 296
Sources: Page: p. 115
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
minor
minor
yes
yes (co-administration study)
Comment: The 90% confidence interval (CI) of the geometric means for hydrocodone AUCinf (98 to 115%), AUCt (98 to 115%), and Cmax (93 to 121%) values were within the range of 80 to 125% when a single dose of HYSINGLA ER 20 mg was co-administered with CYP2D6 inhibitor paroxetine
yes
yes (co-administration study)
Comment: Co-administration of HYSINGLA ER and CYP3A4 inhibitor ketoconazole increased mean hydrocodone AUC and Cmax by 135% and 78%, respectively;
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Profound hearing loss associated with hydrocodone/acetaminophen abuse.
2000 Mar
[Longitudinal study of parameters of respiratory function tests and blood gas analysis in patients with progressive systemic scleroderma].
2001
Opioid formulations: tailoring to the needs in chronic pain.
2001
Randomized, prospective, double-blind, placebo-controlled trial of effect of nitroglycerin ointment on pain after hemorrhoidectomy.
2001 Aug
Psychosis after ultrarapid opiate detoxification.
2001 Jun
Who's feeling no pain?
2001 Mar 19
Evaluation of urinary dihydrocodeine excretion in human by gas chromatography-mass spectrometry.
2001 Mar 5
Narcotic analgesics for dental pain: available products, strengths, and formulations.
2001 Mar-Apr
Important drugs for cough in advanced cancer.
2001 Nov
Acetaminophen, aspirin, or Ibuprofen in combination analgesic products.
2001 Nov-Dec
Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial.
2001 Sep
Engineering novel biocatalytic routes for production of semisynthetic opiate drugs.
2001 Sep
The simultaneous determination of codeine, morphine, hydrocodone, hydromorphone, 6-acetylmorphine, and oxycodone in hair and oral fluid.
2002 Apr
[Hospital maternal mortality: causes and consistency between clinical and autopsy diagnosis at the Northeastern Medical Center of the IMSS, Mexico].
2002 Feb
Gateways to clinical trials.
2002 Jul-Aug
Photodynamic therapy for Barrett's esophagus and high grade dysplasia: results of a patient satisfaction survey.
2002 Jul-Aug
A double-blind, single-dose comparison of the analgesic efficacy of tramadol/acetaminophen combination tablets, hydrocodone/acetaminophen combination tablets, and placebo after oral surgery.
2002 Jun
Simultaneous determination of hydrocodone and hydromorphone in human plasma by liquid chromatography with tandem mass spectrometric detection.
2002 Mar 25
[Trends in the incidence of hepatic tumors in childhood].
2002 Mar-Apr
Gender differences in narcotic-induced emesis in the ED.
2002 May
Exacerbation of panic disorder symptoms following Vicodin exposure.
2002 Nov-Dec
Rational use of analgesic combinations.
2002 Oct
A field evaluation of five on-site drug-testing devices.
2002 Oct
Detection of cocaine analytes and opiates in nails from postmortem cases.
2002 Oct
Determination of 6-oxo-morphinans, as the oximes, by difference circular dichroism spectroscopy.
2002 Oct
Effect of gastrointestinal bleeding and oral medications on acquisition of vancomycin-resistant Enterococcus faecium in hospitalized patients.
2002 Oct 15
Senate committee fights hydrocodone abuse.
2002 Sep
[Hypoxic brain damage in victims of fatal road traffic accident: prevalence, distribution and association with survival time and other head and extracranial injuries].
2002 Sep
Review of the analgesic efficacy of ibuprofen.
2003 Apr
Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.
2003 Aug
The synergistic analgesic interactions between hydrocodone and ibuprofen.
2003 Dec
Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers.
2003 Jan
Hair analysis for opiates: evaluation of washing and incubation procedures.
2003 Jun 5
Rapid communication: laparoscopic Anderson-Hynes dismembered pyeloplasty using the da Vinci robot: technical considerations.
2003 Mar
Misuse of prescribed controlled substances defined by urinalysis.
2003 Mar-Apr
The influence of gender and race on physicians' pain management decisions.
2003 Nov
Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II.
2003 Nov-Dec
Carisoprodol withdrawal syndrome.
2004 Dec
Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors.
2004 Feb
Efficacy of ibuprofen-hydrocodone for the treatment of postoperative pain after periodontal surgery.
2004 Jun
Fatal intravenous fentanyl abuse: four cases involving extraction of fentanyl from transdermal patches.
2004 Jun
Patient-controlled ropivacaine analgesia after arthroscopic subacromial decompression.
2004 May
Cough suppression during flexible bronchoscopy using combined sedation with midazolam and hydrocodone: a randomised, double blind, placebo controlled trial.
2004 Sep
A 46-year-old man with excruciating shoulder pain.
2005 Mar
Patents

Sample Use Guides

APADAZ Immediate-release tablets: 6.12 mg benzhydrocodone (equivalent to 6.67 mg benzhydrocodone hydrochloride) and 325 mg acetaminophen. Initiate treatment with APADAZ at 1 or 2 tablets every 4 to 6 hours as needed for pain. Dosage should not exceed 12 tablets in a 24­ hour period.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 07:32:51 GMT 2023
Edited
by admin
on Sat Dec 16 07:32:51 GMT 2023
Record UNII
NO70W886KK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROCODONE BITARTRATE
ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
USAN  
Official Name English
HYDROCODONE BITARTRATE COMPONENT OF ALLAY
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF TUSSIGON
Common Name English
HYDROCODONE TARTRATE
MART.  
Common Name English
CODAMINE COMPONENT HYDROCODONE BITARTRATE
Common Name English
TUSSIGON COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYSINGLA
Brand Name English
HYDROCODONE BITARTRATE COMPONENT OF ANEXSIA
Common Name English
NORCO COMPONENT HYDROCODONE BITARTRATE
Common Name English
ZUTRIPRO COMPONENT HYDROCODONE BITARTRATE
Brand Name English
HYDROCODONE BITARTRATE [USAN]
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF LORCET-HD
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF REZIRA
Brand Name English
HYDROCODONE BITARTRATE COMPONENT OF VICODIN
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF REPREXAIN
Common Name English
DURADYNE DHC COMPONENT HYDROCODONE BITARTRATE
Common Name English
REPREXAIN COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE [ORANGE BOOK]
Common Name English
DIHYDROCODEINONE BITARTRATE HYDRATE
Common Name English
OBREDON COMPONENT HYDROCODONE BITARTRATE
Brand Name English
HYDROCODONE BITARTRATE [USP MONOGRAPH]
Common Name English
NORCET COMPONENT HYDROCODONE BITARTRATE
Common Name English
LORCET-HD COMPONENT HYDROCODONE BITARTRATE
Common Name English
DICODID
Brand Name English
HYDROCODONE BITARTRATE COMPONENT OF HYCODAN
Common Name English
HYDROCODONE BITARTRATE CII
USP-RS  
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF FLOWTUSS
Brand Name English
VICODIN COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE [VANDF]
Common Name English
AZDONE COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF OBREDON
Brand Name English
HYDROCODONE BITARTRATE COMPONENT OF VICOPRIN
Common Name English
ALLAY COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYCODAN
Brand Name English
HYDROCODONE BITARTRATE COMPONENT OF ZYDONE
Common Name English
HY-PHEN COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF NORCET
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF LORTAB
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF HY-PHEN
Common Name English
HYDROCODONE TARTRATE [MART.]
Common Name English
MERCODINONE
Brand Name English
HYCOFENIX COMPONENET OF HYDROCODONE BITARTRATE
Brand Name English
HYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE
EP  
Common Name English
Hydrocodone bitartrate [WHO-DD]
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF CODAMINE
Common Name English
REZIRA COMPONENT HYDROCODONE BITARTRATE
Brand Name English
HYDROCODONE BITARTRATE COMPONENT OF DURADYNE DHC
Common Name English
4,5α-Epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5)
Common Name English
VANTRELA
Brand Name English
HYDROCODONE BITARTRATE COMPONENT OF HYCOMINE
Common Name English
LORTAB COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF ZUTRIPRO
Brand Name English
HYCOMINE COMPONENT HYDROCODONE BITARTRATE
Common Name English
ZOHYDRO
Brand Name English
HYDROCODONE BITARTRATE HEMIPENTAHYDRATE [MI]
Common Name English
CEP-33237
Code English
HYDROCODONE BITARTRATE COMPONENT OF CO-GESIC
Common Name English
ANEXSIA COMPONENT HYDROCODONE BITARTRATE
Common Name English
TYCOLET COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF HYCOFENIX
Brand Name English
BANCAP HC COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF TYCOLET
Common Name English
VICOPROFEN COMPONENT HYDROCODONE BITARTRATE
Common Name English
MORPHINAN-6-ONE, 4,5-EPOXY-3-METHOXY-17-METHYL-, (5.ALPHA.)-, (2R,3R))-2,3-DIHYDROXYBUTANEDIOATE (1:1), HYDRATE (2:5)
Common Name English
HYDROPANE COMPONENT HYDROCODONE BITARTRATE
Common Name English
CO-GESIC COMPONENT HYDROCODONE BITARTRATE
Common Name English
ZYDONE COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYCODAN COMPONENT HYDROCODONE BITARTRATE
Common Name English
HYDROCODONE BITARTRATE CII [USP-RS]
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF NORCO
Common Name English
HYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE [EP MONOGRAPH]
Common Name English
HYDROCODONE BITARTRATE HEMIPENTAHYDRATE
MI  
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF HYDROPANE
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF VICOPROFEN
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF BANCAP HC
Common Name English
HYDROCODONE BITARTRATE COMPONENT OF AZDONE
Common Name English
FLOWTUSS COMPONENT HYDROCODONE BITARTRATE
Brand Name English
VICOPRIN COMPONENT HYDROCODONE BITARTRATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C67413
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
NCI_THESAURUS C66917
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
DEA NO. 9193
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
NCI_THESAURUS C1506
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
Code System Code Type Description
RS_ITEM_NUM
1315001
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
PRIMARY
DRUG BANK
DBSALT001233
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
PRIMARY
EVMPD
SUB02559MIG
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
PRIMARY
EPA CompTox
DTXSID7091543
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
PRIMARY
CAS
34195-34-1
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
PRIMARY
PUBCHEM
23724881
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
PRIMARY
SMS_ID
300000040282
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
PRIMARY
DAILYMED
NO70W886KK
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
PRIMARY
ChEMBL
CHEMBL1457
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
PRIMARY
RXCUI
142439
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
PRIMARY RxNorm
FDA UNII
NO70W886KK
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
PRIMARY
CHEBI
5780
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
PRIMARY
MERCK INDEX
m6093
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
Hydrocodone bitartrate
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
PRIMARY
NCI_THESAURUS
C29099
Created by admin on Sat Dec 16 07:32:51 GMT 2023 , Edited by admin on Sat Dec 16 07:32:51 GMT 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.2
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY